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Background: Accumulation and deposition of β-amyloid peptides (Aβ) in the brain is a central event in the pathogenesis
of Alzheimer’s disease (AD). Besides the parenchymal pathology, Aβ is known to undergo active transport across
the blood–brain barrier and cerebral amyloid angiopathy (CAA) is a prominent feature in the majority of AD.
Although impaired cerebral blood flow (CBF) has been implicated in faulty Aβ transport and clearance, and
cerebral hypoperfusion can exist in the pre-clinical phase of Alzheimer’s disease (AD), it is still unclear whether it
is one of the causal factors for AD pathogenesis, or an early consequence of a multi-factor condition that would
lead to AD at late stage. To study the potential interaction between faulty CBF and amyloid accumulation in
clinical-relevant situation, we generated a new amyloid precursor protein (APP) knock-in allele that expresses humanized
Aβ and a Dutch mutation in addition to Swedish/London mutations and compared this line with an equivalent knock-in
line but in the absence of the Dutch mutation, both crossed onto the PS1M146V knock-in background.
Results: Introduction of the Dutch mutation results in robust CAA and parenchymal Aβ pathology, age-dependent
reduction of spatial learning and memory deficits, and CBF reduction as detected by fMRI. Direct manipulation of CBF
by transverse aortic constriction surgery on the left common carotid artery caused differential changes in CBF in the
anterior and middle region of the cortex, where it is reduced on the left side and increased on the right side. However
these perturbations in CBF resulted in the same effect: both significantly exacerbate CAA and amyloid pathology.
Conclusions: Our study reveals a direct and positive link between vascular and parenchymal Aβ; both can be
modulated by CBF. The new APP knock-in mouse model recapitulates many symptoms of AD including progressive
vascular and parenchymal Aβ pathology and behavioral deficits in the absence of APP overexpression.
Keywords: Alzheimer disease, Parenchymal plaque, Cerebral amyloid angiopathy (CAA), Dutch mutation, Cerebral
blood flow (CBF), Transverse aortic constriction (TAC)Background
Deposition of β-amyloid peptides (Aβ) derived from the
proteolytic processing of the amyloid precursor protein
(APP) in the brain is a defining pathological hallmark of
Alzheimer’s disease (AD) [1]. Although most AD cases
are late-onset, a small percentage of individuals develop* Correspondence: huiz@bcm.edu
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unless otherwise stated.early-onset AD due to the presence of autosomal domin-
ant mutations in APP, PSEN1 or PSEN2. These familial
AD (FAD) mutations are known to alter the production
of Aβ, leading to accelerated amyloid pathology. Besides
the parenchymal Aβ, cerebral amyloid angiopathy (CAA) is
frequently observed in aged human brains and is present in
majority of AD and vascular cognitive impairment patients
(reviewed by [2]). It is known that Aβ undergoes active
transport across the blood–brain barrier (BBB) [3,4]. Ac-
cordingly, BBB impairment and/or age-associated reduction
of cerebral blood flow (CBF) has been speculated to con-
tribute to faulty Aβ clearance in late-onset AD ([5] andhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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and clinical trials of Aβ vaccination have shown to enhance
brain to plasma Aβ efflux [7,8], leading to aggravated CAA
and microhemorrhages [9-13]. However, contradicting ob-
servations were also reported that intraperitoneal adminis-
tration of antibody 266 retarded Aβ clearance from the
brain [14]. While the reason for the different outcomes
remains to be established, it argues for the importance
to understand the relationship between vascular and
parenchymal Aβ, as well as their interactions with
cerebral hemodynamics.
Whereas most of the APP FAD mutations lead to
early-onset familial AD with variable CAA, the APP
E693Q (E22Q of Aβ) mutation is known to cause heredi-
tary cerebral hemorrhage with amyloidosis of Dutch type
(HCHWA-D, herein referred to as Dutch) with affected
brains exhibiting extensive CAA but limited parenchy-
mal Aβ deposits [15]. Accordingly, various transgenic
mouse lines expressing different APP FAD mutations
have been created to model AD and/or CAA (www.alz
forum.org/research-models for current list). However,
these animals overexpress transgenes ectopically, which
confound the analysis of AD-relevant pathways [16]. In-
deed, it has been increasingly recognized that at least
some of the phenotypes reported were due to APP over-
expression independent of Aβ pathology [17-19].
To facilitate the development of CAA and AD neuro-
pathology in the absence of overexpressing the exogen-
ous APP, we created a new APP knock-in mouse that
expresses humanized Aβ containing the Dutch mutation
in addition to Swedish/London mutations, and com-
pared this line with an equivalent knock-in line but
without the Dutch mutation [20,21]. We found that in-
clusion of the Dutch mutation is associated with age-
dependent reduction of CBF, accelerated CAA and Aβ
deposition and behavioral deficits. Further, manipulation
of CBF by aortic constriction leads to global enhance-
ment of Aβ pathology in both brain parenchyma and
cerebral blood vessels, thus revealing a potent and direct
regulation of Aβ pathology by CBF.
Results
Generation and biochemical analysis of APP DSL knock-in
mice
We replaced exons 16 and 17 of the mouse APP gene
with mutant sequences harboring the Swedish (K670N,
M671L), Dutch (E693Q, amino acid 22 of Aβ), and
London (V717I, all in APP770 numbering) FAD mutations
together with humanized Aβ sequence by homologous re-
combination (Figure 1A and B), so that expression of the
mutant APP and human Aβ is subject to its endogenous
physiological regulations. In the knock-in vector, a pair of
loxP sites were inserted to flank the truncated exon16 (that
stops before the mouse Aβ sequence) and the neo-cassette;followed by the mutant exon 16 encoding the Swedish
mutation and humanized Aβ sequence, and the mutant
exon 17 containing the Dutch and London mutations
(Figure 1A). Mice containing the targeted allele were then
crossed with a germline Cre-deleter [22] to remove the
truncated exon 16 and the neo-cassette and to express APP
with the Dutch/Swedish/London mutations and humanized
Aβ sequence.
Preliminary analysis showed that, similar to the APP
Swedish/London knock-in mice, the APP Dutch/Swed-
ish/London mice develop minimal Aβ deposits in their
life time, we accordingly bred both lines with the PS1
M146V knock-in mice [23-25] to facilitate the develop-
ment of amyloid pathology within the aging time span of
the mice. All subsequent studies were performed in the
APP and PS1 M146V double homozygous background,
listing the line with Swedish/London mutations and
Dutch/Swedish/London as APP SL and APP DSL,
respectively.
As expected, the APP DSL knock-in mice express
similar levels of APP in comparison with that of wild-
type mice and with an existing APP knock-in line
expressing Swedish and London mutations and hu-
manized Aβ sequence (APP SL) [20,21] (Figure 1C and
quantified in 1D). Therefore, the APP DSL and APP SL
knock-in lines are otherwise identical except the
addition of the Dutch mutation in the APP DSL mice. .
APP DSL knock-in mice exhibit accelerated amyloid
pathology
We performed sandwich ELISA to measure Aβ1-40
(Aβ40) and Aβ1-42 (Aβ42) concentrations in detergent
soluble and insoluble fractions of brain lysates from
young (Y, ~6 months), middle-age (M, 10 ~ 12 months),
and old (O, 18 ~ 20 months) APP SL and APP DSL mice
(Figure 2). Lysates from wild-type mice were used as a
background control. We found that levels of Aβ40 and
Aβ42 peptides in detergent-soluble fractions were com-
parable in young (light grey) and middle-age (dark grey)
groups of APP DSL mice, but both were significantly
elevated at old age (black bars Figure 2A and B). In con-
trast, a substantial elevation of insoluble Aβ40 and Aβ42
could already be detected in middle-aged APP DSL
group compared to the young mice (Figure 2C and D),
which is correlated with the beginning of amyloid depos-
ition at this time frame (Figure 2E). Levels of insoluble
Aβ, in particular Aβ42 (Figure 2D), increased sharply in
old APP DSL mice, consistent with extensive amyloid
deposition at this age (Figure 2E, 2F and quantified in
2G). These results indicate that the middle-age marks a
critical stage when the APP DSL mice are no longer able
to effectively maintain Aβ homeostasis, leading to ele-
vated insoluble Aβ accumulation. The rise of soluble Aβ
in addition to insoluble Aβ in old age likely reflects the
Figure 1 Generation of APP DSL knock-in mice. A. Gene targeting strategy to generate the APP DSL knock-in allele. Wild type mouse exon 16
and 17 (E16, E17) were replaced by a truncated exon 16 (truncE16), double neo-cassette, followed by exon 16 with humanized Aβ sequence and
the Swedish mutation (E16*), and exon 17 with the Dutch and London mutations (E17*). TruncE16 and the neo-cassette were flanked by two loxP
sites, which were removed after cre-excision. DT: diphtheria toxin, which was lost upon homologous recombination. B. Schematic diagram of
amino acid alterations in APP DSL knock-in line. Aβ42 sequence is marked by thin underline. Residues mutated to humanize Aβ are shown in
bold and italic; residues with FAD mutations (Swedish: NL, Dutch: Q, and London: I) are shown in thick-underline. TM: transmembrane region.
C. Expression of APP is similar in brain lysates of 3-month-old wild type (WT), SL and DSL knock-in lines, as detected by western blot using
antibody against the N-terminal region of APP (22C11) or humanized Aβ region (6E10). γ-tubulin was used as loading control. WT: wild type;
SL: APP with humanized Aβ region and Swedish and London mutations; DSL: APP with humanized Aβ region and Swedish, Dutch, and
London mutations. D. Quantification of C.
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late hippocampus for ELISA and plaque pathology due
to the fact the plaque pathology was prominent only in
the old age group of APP DSL mice in hippocampus,
thus Aβ in total tissue lysate in ELISA and plaques in
whole cortical area were used to indicate the progression of
Aβ accumulation. In contrast to the APP DSL mice, Aβ
levels and positive Aβ staining could only be detected in
old APP SL mice (Figure 2, SL), but not in young and
middle-age groups, when SL samples were prepared the
same way as DSL samples. Therefore, introduction of the
Dutch mutation leads to elevated steady-state Aβ levels
across all ages and accelerated amyloid pathology.
Anxiety-like behavior and cognitive impairment in APP
DSL mice
We previously reported that the APP SL knock-in mice
exhibit anxiety phenotypes starting at young age [20].Analysis of young APP DSL mice revealed that these mice
also display enhanced anxiety-like behaviors assayed by ele-
vated plus maze with less distance traveled on the open
arm than that of wild type mice (Figure 3A), and by condi-
tioned fear assay with higher percentage of freezing time
that was induced in a new environment (Figure 3B). These
phenotypes persisted in middle-age animals. The enhanced
freezing made it difficult to evaluate memory functions
using the classical conditioned fear paradigm. We thus used
the Morris water maze (MWM) to assess the spatial learn-
ing and memory abilities in APP DSL mice in young and
middle-age groups and compared that with age-matched
APP SL knock-in lines. APP DSL mice displayed normal
spatial learning and memory at young age (Figure 3C
and 3D). However, significant learning and memory deficits
can be detected when APP DSL mice reached to middle
age, as shown by longer latency to reach the hidden plat-
form in the learning sessions (Figure 3E), and less duration
Figure 2 Aβ levels and amyloid pathology in APP DSL and APP SL mice. A and B. Sandwich ELISA analysis of Aβ1-40 (Aβ40, A) and Aβ1-42
(Aβ42, B) levels in Triton X100 soluble fractions of young (Y, ~ 6 month), middle (M, 10 ~ 12 month), and old (O, 18 ~ 20 month-double check
Result section) of APP DSL and APP SL brain lystates. C and D. Aβ40 (D) and Aβ42 (E) levels in Triton X100 insoluble fractions of the corresponding age
groups in A & B. WT: Wild type brain lysate, used as background control. Values of APP SL mice in only the old aged group was shown since the young
and middle age groups were at background levels. E. upper panel, Aβ immunostaining using the anti- antibody showing age-dependent increases of
parenchymal plaque in APP DSL knock-in mice. F. Fluorescent images demonstrate the consistence between the antibody staining and Thioflavin S (ThioS)
staining. G. Quantification of percentage of plaques in whole cortical areas. N = 3 mice/genotype for young and old age group, and n = 5 mice for APP
DSL middle age group. ***p < 0.001. Scale bar: 100 μm.
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test (Figure 3F). We subsequently investigated whether
spatial related working memory is also affected in the APP
DSL knock-in mice. Additional training was provided to
allow the APP DSL reaching to the same level as the wild-
type controls (Day 8) before they underwent reverse learn-
ing sessions (Day 9 ~ 12 in Figure 3G & H). During the
following reverse-learning tests when the location of the
hidden platform was switched from Quadrant 3 to Quad-
rant 4, the APP DSL mice extinguished the memory of the
old location similarly as their wild type controls. However
they formed the memory of the new location significantly
slower than their wild-type controls (Figure 3H). The APP
DSL mice were able to reach to a comparable level as wildtype controls in the memory test at the last day of training,
suggesting that their working memory deficits were at an
early stage and could be corrected by intensive training
(Day 12 in Figure 3H). Different from the APP DSL mice,
the APP SL mice of the same age group demonstrated nor-
mal latency in locating the hidden platform in the training
sessions as well as similar preference to the targeted quad-
rant in the probing test (Figure 3I and J). Old group of APP
DSL mice exhibited the same anxiety behavior and learning
and memory deficits as the middle age group, comparing
with age and gender matched wild type controls (>18-
month of age, n = 11 per genotype, Additional file 1). Since
insoluble, but not soluble, Aβ were significantly increased
in middle-aged APP DSL mice, the behavioral results
Figure 3 Abnormal behaviors in knock-in mice. Enhanced anxiety in both SL and DSL knock-in lines, but the memory impairments only in DSL mice
starting at middle age. A. SL and DSL travels shorter distance on the open arms than wild type mice in elevated plus maze, indicating enhanced anxiety in
these knock-in mice starting at young age. B. During the first 3 minutes when these mice were introduced to a new environment 24 hours after receiving
a mild foot shock, both SL and DSL knock-in mice had higher percentage of time freezing in both young and middle aged group. C-J. Spatial learning
and memory assays by Morris water maze (MWM). DSL exhibited normal learning and memory abilities when they are young (4-month old) (C & D). But
the middle-aged group were slow in reaching the hidden platform during learning (E) and showed memory deficits at elderly age (12-month old) (F), in
comparison with age and sex matched wild type control (WT). After additional day of training for DSL to learn the hidden platform tests, the platform was
switched from Quadrant 3 (Q3) to Quadrant 4 (Q4) the following week to test reverse learning (G and H). DSL mice lagged behind WT in learning the
new position on Day 11 and 12 (G), and in forming the new memory about the hidden platform on Day 10 and 11 (H). In comparison with DSL, SL mice
behaved normally in spatial learning and memory at the same aged period (12-month old) (I & J). 10 ~ 18 male mice were used for each genotype at each
age group. All mice used were novice to these behavior assays. NS, not significant; *P < 0.05, **P < 0.01, ***P<0.001.
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uble Aβ accumulation. However, since ELISA was carried
out using the whole hemisphere of the brain, we cannotexclude the possibility that there might be local changes of
soluble Aβ levels in the middle aged group that were not
observed from total tissue lysate.
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knock-in mice
Since the Dutch mutation is known to cause CAA in
humans, we next examined the CAA pathologies in APP
DSL mice and compared these with the APP SL mice.
Minimal CAA could be detected in APP DSL animals at
young age (Figure 4A). However, prominent CAA could
be observed when the mice reached to middle-age and
became more severe as the mice aged (Figure 4A and
quantified in 4B). No CAA could be detected in APP SL
mice until they reached to terminal age (>28 month,
Additional file 2). Therefore, inclusion of the Dutch mu-
tation leads to a simultaneous increase of both vascular
and parenchymal Aβ pathologies starting at middle-age.
Since Aβ accumulation surrounding blood vessels is
known to increase the risk of intracranial hemorrhage and
hemorrhagic stroke in human brains [26-28], we wanted to
know whether similar pathology could also develop in APP
DSL mice. We thus performed Prussian blue reaction to re-
veal iron released by hemosiderin in coronal sections of
APP DSL mice and their age- and sex-matched wild-type
controls and APP SL mice. No Prussian blue-positive sig-
nals could be spotted in cortical areas of wild-type or APPFigure 4 Cerebral amyloid angiopathy and microhemorrhages in APP
accumulate Aβ (red) around middle age (9 ~ 10 month of age), and becam
B (percent of smooth muscle-actin area covered by amyloid). Sm-actin, sm
at old age, as seen by Prussian blue staining. No blue sport detected on co
middle age mice; but DSL old age mice (>17 month) frequently have micr
number of spots = 1.35 ± 0.46 per section, N = 10 sections/mouse from 5
in C inset.SL mice at any age (Figure 4C). While this was also the case
in young and middle-age APP DSL mice, microhemorrhage
became obvious in old APP DSL mice (Figure 4C, with
average number of spots = 1.35 ± 0.46 per section, counted
in 5 animals, 10 sections per animal). The microhemor-
rhages were almost exclusively located in the cortical region
suggesting their association with amyloid buildup around
cortical blood vessels. The fact that the onset of micro-
hemorrhage is several months after the CAA supports
the notion that CAA leads to the development of intra-
cranial hemorrhage. Overall, the APP DSL knock-in
mice recapitulate many of the pathological hallmarks
associated with AD including age-dependent CAA and
CAA-associated microhemorrhage.
Because a prominent age-associated vascular Aβ path-
ology could be observed in the APP DSL mice, we asked
whether CAA lead to changes in CBF in these mice.
Using a MRI arterial spin labeling method, we measured
relative cerebral blood flow (rCBF) in cortical regions of
young, middle-age, and old wild-type and APP DSL
mice (Figure 5). As expected, age-associated reduction
of rCBF exists even in wild type mice (Figure 5B, open
bars). Interestingly, the APP DSL mutant mice at youngDSL mice. A. Cerebral blood vessels (green) in DSL mice start to
e more extensively covered by amyloid at old age, as quantified in
ooth muscle actin to mark blood vessels. C. Microhemorrhage in DSL
rtical area of any age of wild type or SL mice, nor in DSL young and
ohemorrhage spots with diameters ranger from 10 ~ 50 μm. Average
animals. **P < 0.01. Scale bars: 50 μm in A, 400 μm in C, and 50 μm
Figure 5 Age-dependent reduction of rCBF in wild type and
APP DSL mice measured by MRI. A. Representative CBF maps for
wild type (WT) and APP DSL knock-in mice at young, middle, and old
ages. B. Quantification of CBF in the cortical area of MRI scans. N = 5-8
mice/genotype/age. NS, not significant; *P < 0.05, **P < 0.01.
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to age-matched wild type controls, although this differ-
ence failed to reach statistical significance. As the mice
aged, APP DSL mice develop much severe reduction in
rCBF than their wild-type controls. We found that rCBF
in APP DSL mutant was reduced to ~60% and ~40% of
the wild-type controls at middle-age and old groups, re-
spectively (Figure 5B), correlating with the severity of
the CAA phenotypes (see Figure 4).
Chronic manipulation of CBF results in global increase of
CAA and plaque load
Having observed an exacerbating effect of CAA on age-
dependent reduction of rCBF in the APP DSL knock-in
mice, we set out to test if manipulation of blood flow
could in turn affect Aβ pathology. We performed trans-
verse aortic constriction surgery (TAC) on the left com-
mon carotid artery on 6 month-old APP DSL mice, a
procedure that causes a substantial decrease of CBF on
the anterior and medial regions of left side and a corre-
sponding increase of CBF on the contralateral side ofthe same areas with minimal effects on the posterior re-
gions. Non-invasive carotid Doppler ultrasound record-
ing [29,30] confirmed the success of the surgery, with
ratios of the peak flow velocity of the left carotid artery
to the right side ranging from 1:6 ~ 1:12. We terminated
the mice at 1.5 or 3 months after the TAC surgery when
animals reached to 7.5 and 9 months old, respectively, to
evaluate the state of CAA and Aβ deposits in the two
hemispheres. We did not detect hemorrhages in these
brains, indicating that there was likely no acute ischemic
insult as might be expected with complete carotid artery
occlusion. No appreciable Aβ staining can be detected in
mice 1.5 months post-TAC, suggesting that the surgical
procedure or attendant anesthesia did not significantly
accelerate the onset of the cerebral or vascular Aβ path-
ology. However, when analyzed 3 months post-TAC sur-
gery, the degree of both CAA (Figure 6A and quantified
in B) and parenchymal Aβ pathologies (Figure 6C and
quantified in D) were much higher in TAC-treated mice
compared to sham-treated controls, the latter were in-
distinguishable to age-matched untreated mice. Interest-
ingly and unexpectedly, increases in CAA and plaque
deposits can be detected in the entire brain irrespective
of left-right hemispheres or anterior-posterior regions.
With the exception of CAA severity between the anter-
ior left and right hemispheres, there were no statistically
significant differences in all other comparisons (Figure 6B
and D). Therefore, perturbation of CBF has a global ef-
fect on CAA and Aβ plaque pathology. This could be
due to that either circulating amyloid-aggregation-prone
factors were produced by regional changes of CBF or
that regional manipulation of CBF results in global im-
pairment of Aβ clearance and thus increased overall
amyloid deposits.
In order to quantify soluble and insoluble Aβ40 & 42
concentrations in different cortical areas in TAC animals
3 months post operation, we dissected cortical tissue
into left/right anterior/posterior parts from Zn-fixed su-
crose cryo-protected frozen TAC and control brains for
ELISA quantification (Figure 6E-H). Since Zn-fixation
and sucrose protect increased tissue weight, we didn’t
convert the final readout into per gram of wet tissue as
we did in Figure 2A-D. Instead, detergent soluble frac-
tions were normalized to the samples’ protein concen-
trations (2.5 mg/ml), and insoluble fractions were
prepared from re-solubilized pellets of guanidine solu-
tion from 10 mg/ml total tissue lysates (details in
Materials and Methods section). We found that insol-
uble Aβ42 is increased in all regions in TAC animals,
correlated with plaque and CAA load analysis, changes
in the soluble Aβ40 and 42 are more prominent in the
anterior region than the posterior region, correspond-
ing to the blood flow changes in the anterior area of
the brain. Again, no differences between left vs right
Figure 6 (See legend on next page.)
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Figure 6 Abnormal cerebral blood flow increases amyloid pathology. A. and C. Representative images of CAA (A) and plaque (C)
pathologies in anterior areas of control, sham-operated and transverse aortic constriction surgery (TAC)-operated APP DSL. TAC was performed on
the left common carotid arteries of 6-month old APP DSL mice that terminated for analysis 3 months post-surgery. B. and D. Quantification of
CAA (B) and plaque (D) load in left and right part of anterior (Ant.) or posterior (Post.) brain regions. Scale bars: 50 μm in A; 200 μm in C. N = 4
animals/group and 10 sections/animal. Coronal sections spanning from Bregma −2.58 ~ −0.58 mm were counted as anterior region;-0.94 ~ 3.64
mm were counted as posterior region. E-H, ELISA analysis of soluble (E and F) and insoluble (G and H) Aβ40 (E and G) and 42 (F and H) on
anterior and posterior cortical areas in both left and right hemispheres. Each sample was measured in duplicates on ELISA plates. N = 3 animals/treatment.
*P < 0.05, **P < 0.01, ***P < 0.001.
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directions are deleterious.
Discussion
To investigate the involvement of neurovasculature in
AD pathogenesis (for reviews: [6,31-33]), we created a
new AD knock-in mouse model (APP DSL) that de-
velops progressive CAA and amyloid pathology in the
absence of transgene overexpression. Comparison of
APP DSL and APP SL knock-in mice revealed that in-
clusion of the Dutch mutation results in not only prom-
inent CAA but also accelerated plaque pathology; the
onset of both coincides with the rise of insoluble Aβ
levels in middle-aged animals. The Dutch mutation also
triggers many age-related changes relevant to AD,
including behavioral deficits, reduction of cerebral
blood flow, and microhemorrhages. Surgical interven-
tion of regional CBF changes in either directions re-
sulted in a global increase on the effects of both CAA
and plaque load.
Various transgenic mouse models expressing mutant
APP with or without mutant PSEN1 under the control
of exogenous promoters have been created to model Aβ
pathology. Analyses of these mice have provided invalu-
able insights into AD pathogenesis. However, to promote
the development of amyloid pathology, these transgenic
models typically overexpress mutant proteins several
fold higher compared to the endogenous proteins. Con-
sidering the various physiological functions of APP and
PS1 in the central nervous system, it has become in-
creasingly clear that at least some of the biochemical
and functional defects observed in these transgenic mice
are due to mutant protein overexpression rather than
pathological lesions (reviewed in [16] and see [17-19] for
recent publications). The knock-in mouse models are
particularly attractive as they express APP with FAD
mutations and humanized Aβ under its endogenous
temporal and spatial regulations throughout life, thus
avoiding the confounding effects of ectopic transgene
overexpression. Except the APP-NL-F and APP-NL-G-F
mice reported recently [19], all other APP knock-in lines
require crossing onto PS1 FAD background to facilitate
Aβ development within a mouse’ life span. Inclusion of
the Beyreuther/Iberian (I716F) mutation in APP-NL-Fand APP-NL-G-F mice drives Aβ42 production at ~30×
higher levels than Aβ40, thus avoiding the necessity of
introducing PS1 mutation. However, the Aβ profiles
expressed in these mice are distinctly different from that
of typical AD. In comparison, although inclusion of the
PS1 M146V knock-in allele is required for APP DSL
mice to develop amyloid pathology, the Aβ40/42 ratio is
comparable to what were observed in aged human
brains and in mild cognitive impairment and AD cases
[34-38]. Even though the APP DSL mice generate an Aβ
variant that only exists in patients with HCHWA-D,
these mice present prominent age-related CAA that is
widespread in AD brains. This feature makes the model
uniquely suitable for studying the role of cerebral vascu-
lature in AD pathophysiology.
We are aware of the potential complications by includ-
ing the PS1 M146V knock-in mutation and, accordingly,
we used APP SL mice with the same PS1 M146V knock-
in line as a control. Behavioral analysis showed that both
APP DSL and APP SL knock-in mice develop anxiety-
like phenotypes at a young age but only the APP DSL
mice exhibit age-dependent spatial learning and memory
impairment, supporting the notion that these cognitive
and non-cognitive phenotypes are mediated by distinct
pathways. This assessment is in agreement with our pre-
vious studies [20,39]. The onset of vascular and paren-
chymal Aβ deposits in the APP DSL knock-in mice
coincides with cerebral hypoperfusion and spatial learn-
ing and memory deficits, thus recapitulates the prevalent
early symptom in AD patients. It is still debatable re-
garding the cause or consequence between CAA and
cerebral hypoperfusion in patients with both patho-
logical symptoms. Our data suggest that higher steady-
state levels of Aβ peptides, especially CAA, can be the
causal factor for disturbance in CBF regulation, mean-
while, we found increased CAA in the setting of hyper-
perfusion as well.
It is known that anesthesia agents such as isoflurane at
1.6 ~ 1.8% concentration can cause vasodilation and in-
creased cerebral blood flow [40]. Since CBF monitored
by ASL MRI was scanned when mice were anesthetized
by isoflurane within the concentration range, the severe
reduction of CBF in the APP DSL mice detected, espe-
cially in old mice, could be a combination of chronic
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to isoflurane-induced CBF change in the knock-in animals.
This is in consistent with published observations in
AD patients and in AD transgenic mice models show-
ing that the existence of impairments in autoregulation
of cerebrovascular blood flow before the onset of
the disease [41-44]. Therefore, the exacerbated age-
dependent CBF reduction observed in APP DSL mice
by MRI could indicate an impaired neurovascular
coupling, resulting in a blunted response to vaso-
regulative stimuli upon challenged states.
Our vessel constriction experiments demonstrate a
direct modulation of CBF and Aβ deposition and a posi-
tive relationship between CAA and parenchymal Aβ.
Contrary to a simple correlation between reduced CBF
and increased Aβ burden, we observed global elevation
of CAA and amyloid plaques in both hemispheres of
mice undergoing aortic constriction surgery, although
CAA appeared to be more sensitive to the regional
changes of blood supply. TAC surgical procedure on the
left common carotid artery is expected to result in blood
flow changes in anterior and middle region of the brain
with hypoperfusion on the left side and hyperperfusion
on the right side, leaving blood flow at the posterior re-
gion intact according to the cerebral vasculature pattern
[45]; this has been verified by fMRI after the surgery
(Additional file 3). The differential changes in CBF on
two hemispheres results in physiological changes in the
same direction, which has been reported previously by
Poulet et al. [46], in which elevated oxidative stress and
BBB permeability were observed in young C57Bl/6 mice
8 weeks post-TAC. APP DSL mice might undergo simi-
lar changes, and in turn, increase overall amyloid path-
ology even though we didn’t detect BBB permeability in
TAC-treated mice. Works from the same research group
on C57Bl/6 J and receptor for advanced glycation end
products (RAGE) knockout mice reported detecting Aβ
deposits near cerebral vasculature in both cortex and
hippocampus 8 weeks after the surgery, and reported
that these amyloid depositions could be modulated by
genetic or pharmacological inhibition of RAGE [47-49].
These results, on one hand are consistent with our
observations that CBF changes in both directions can
aggravated amyloid pathology, but on the other hand are
different from our observations in that we did not ob-
serve amyloid deposit in wild type mice (C57Bl/6 J), nor
can we detect amyloid deposits in our APP-DSL knock-
in mice of the same young age group (3-month of age)
12 weeks post TAC surgery (data not shown). This discrep-
ancy might result from differences in staining procedures
as well as the difference in post-surgery time points. It is
also intriguing that previous reports observed increasing
amyloid depositions post-TAC in hippocampus [46-49],
which we failed to see. Considering the fact that bloodsupply to hippocampus is from branches from vertebral ar-
teries, CBF in the hippocampus would not be expected to
be decreased by TAC. Since ischemia is known to trigger
inflammation and production of reactive oxygen species
(reviewed in [50]), it is possible that both regional hypoper-
fusion and hypertension are able to produce circulating fac-
tors (such as oxidative stress factors and inflammatory
cytokines) that spread throughout the brain to regions
where CBF has not been affected. These physiological
changes from disturbances of cerebral hemodynamics in
either direction, in turn, bring about an imbalance of Aβ
production and clearance, and thus accelerates amyloid
accumulation.Conclusions
In summary, the new APP DSL knock-in mouse model re-
capitulates critical features relevant to AD, including CAA,
parenchymal Aβ plaques, cognitive impairments, cerebral
hypoperfusion and microhemorrhage, in an age-dependent
manner. These stages of pathological progression makes it
an attractive model to decipher the relationship between
vascular and parenchymal pathologies and to test the func-
tional consequences by targeting these two pathologies in
the absence of the confounding effects of transgene overex-
pression. Our findings support a model whereby regional
reduction of CBF initiates a vicious cycle by causing wide-
spread aggravation of amyloid pathology, which in turn
leads to further deficits in CBF and exacerbation of Aβ and
CAA pathology.Materials and methods
Animals
All research and animal care procedures were approved
by the Baylor College of Medicine Institutional Animal
Care and Use Committee. PS1 M146V knock-in mice
[23,24] and APP knock-in mice carrying Swedish and
London mutations and humanized Aβ region (APP SL)
were previously published. APP DSL knock-in mice with
Dutch/Swedish/London mutations and humanized Aβ
region was generated in the similar manner as previously
published APP/hAβ/mutC [25], except that the Dutch
mutation (E618Q, APP695 numbering) was incorporated
by site-directed mutagenesis when constructing the
gene-targeting vector. Briefly, exons 16 and 17 of mouse
APP were replaced by the mutant construct from the
knock-in vector by homologous recombination, in which
a pair of loxP sites flanked truncated exon 16 and neo-
cassette, followed by mutant exon 16 with Swedish mu-
tation (KM595-596NL) and humanized Aβ sequence
(G601R, F606Y, and R609H), and then mutant exon 17
carrying Dutch mutation (E618Q) and London mutation
(V642I) (Figure 1A). Genotyping was done by PCR using
primers:




CG-3′, which amplifies the loxP site. Expected PCR
product from the wild type allele is 230 bp, and from
the targeted allele is 270 bp.
The mice were then crossed with a germline Cre-
deleter [22] to remove the truncated exon 16 and the
neo-cassette and to produce APP with Dutch/Swedish/
London mutations and humanized Aβ sequence. Cross-
ing with PS1 M146V knock-in mice generate APP/PS1
homozygous double knock-in mice.
Sandwich ELISA
For Figure 2A-D, brain halves were weighted and ho-
mogenized in 4× (w/v) homogenization buffer composed
of PBS, 1% Triton X100 and complete protease inhibitor
cocktail (Roche). Total brain lysates were centrifuged at
100,000x g at 4°C for 1 hour and supernatants were di-
luted in half to be applied to Aβ1-40 and Aβ1-42 ELISA
kit (Invitrogen, #KHB3481 and #KHB3544) following the
company’s protocol. The resulting pellets (insoluble frac-
tions) were resuspended in 5 M guanidine HCl/50 mM
Tris HCl, pH8.0, rotated at room temperature for
4 hours, and centrifuged at 20,000×g for 20 minutes. Su-
pernatants from the last step centrifugation were diluted
500 ~ 2000 fold before applying to the ELISA kits. Each
sample was analyzed in duplicate. Three to five male an-
imals were used for each genotype at each age group.
For Figure 6E-H, 9-month-old male mice (with or
without transverse aortic constriction surgery (TAC) at
6 months) were perfused and fixed using Zn-fixatives.
The retrieved brains were cryoprotected by soaking in
30% sucrose for 36 hours and frozen in −80°C before
ELISA experiment. To obtain cortical tissue for left/right
anterior/posterior region, mouse brain was put into
acrylic 1 mm adult mouse brain matrix for coronal slices
to remove olfactory bulbs and cerebella. Cutting in the
mid-line separates left vs right half of the brain, cutting
in the 5 mm slot separates anterior and posterior region.
Corresponding parts of cortex were then peeled off and
detergent soluble and insoluble lysate were prepared as
mentioned in the above paragraph. Due to Zn-fixation
and sucrose cryoprotection, the tissue weighted heavier
than un-perfused tissue used for Figure 2A-D, rendered
it impossible to deduce comparable Aβ concentration in
per gram of wet tissue as before. Thus, ELISA results for
soluble samples were normalized to the protein concen-
tration of 2.5 mg/ml. For insoluble fractions, 300 ul of
10 mg/ml of total tissue lysate were centrifuged for
1 hour at 100,000×g 4°C; resulting pellets were re-
solubilized in 200 ul of guanidine solution as in the
above paragraph, and diluted 20× before applying toELISA plates. All data in this group were presented as
pg/ml instead of converting to pg/g of wet tissue. All
samples were analyzed in duplicates on ELISA plates,
and 3 male animals were used for each group of
treatment.
Immunofluorescence, immunohistochemistry staining
(PFA or Zinc fixed), and amyloid load quantification
Antibody staining on paraffin-embedded brain sections was
performed as described [24]. In particular, paraformalde-
hyde (PFA) perfused brains were cut into 10 μm paraffin
sections. The sections were deparaffinized in xylene, then
rinsed with series of ethanol and water mixture. Antigen-
retrieval was done by incubating sections with 70% formic
acid for 6 minutes. Endogenous peroxidase activity was
quenched by incubating the slides in 0.3% H2O2 for 30 mi-
nutes. The slides were rinsed with Tris-buffered saline
(TBS; 50 mM Tris-Cl, pH 7.5 and 250 mM NaCl). Nonspe-
cific epitopes were blocked for 30 minutes with 3% normal
goat serum, 0.4% Triton X-100 in TBS. Primary antibodies
against smooth muscle actin (Sigma, A2547) and/or Aβ
(Cell Signaling, #2454) were diluted 1:1000 in blocking buf-
fer, and incubated overnight at 4 ° C in a humid chamber.
Sections were then washed 3 x 5 minutes each in TBS and
incubated with anti-mouse-Alexa 488 and/or anti-rabbit-
Alexa 555 secondary antibodies at room temperature for
1 ~ 2 hours. Pictures were taken with a Leica TCS SPE
microscope and the images were processed with ImageJ
(National Institute of Health). Mice underwent aortic band-
ing surgery were fixed in a similar manner but using
Zinc-fixation [51] (0.1 M Tris–HCl pH7.4, 0.05% Calcium
acetate, 0.5% Zinc acetate, 0.5% Zinc chloride) instead of
PFA. Immunohistochemistry on Zn-fixed brain sections
were done using alkaline-phosphatase standard method
(Vector Laboratories, AK-5000) and corresponding alkaline
phosphatase substrate kit (Vector Laboratories, SK-5100).
Prussian blue staining for microhemorrhage
Cryosections of WT, SL, and APP DSL mice were
mounted on glass slides and dried overnight. Slides were
immersed in freshly mixed 4% Potassium Ferrocyanide
with 4% of hydrochloric acid, and microwaved for 30 sec-
onds. Then rinsed in tap water for 3×10 minutes. Next,
slides were counter stained using nuclear fast red at
room temperature for 5 minutes, rinsed under running
tap water for 1 minutes, dehydrated quickly in 95% and
100% ethanol, cleared in xylene, covered by mounting
medium and coverslips for imaging. 3 ~ 4 male animals
were used for each genotype at old age group as well as
APP DSL in middle age group.
Behavioral assays
Mice were housed in a 12 hour light/12 hour dark cycle.
All behavior tests were done on naïve male mice at
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old) ages. 10 ~ 18 male animals were used for each geno-
type at each age group. Mice were tested in elevated plus
maze first, conditioned fear experiment two days after,
and the Morris water maze one week later.
Elevated Plus Maze (EPM)
The testing room was at 700 LUX illumination, with
60 dB white noise. Mice were brought to the room in
their home cages and allowed to acclimate for 1 hour
before starting the test. The testing apparatus is a plus-
shaped platform made of white plastics, elevated 50 cm
above the ground, with each arm 30×5 cm. Extended
from a 5×5 cm center area are two opposite high-walled
enclosed arms and two open arms (with a shallow rim
along the side). The mouse being tested was placed in
the center area and allowed to explore the plus maze for
10 minutes. Entrances, duration, and distance traveled in
each region were recorded by a camera connected to an
automated ANY-maze tracking system (Version 4.50;
Stoelting, Co., Wood Dale, IL, USA). The platform was
cleaned with 70% isopropanol after each trial. All mice
were novel to the test, and EPM is the first behavior test
performed on these mice.
Conditioned Fear (CF)
Mice were transported to the holding room in their
home cages 30 minutes prior to the test on the training
and test days. On the first day (training sessions), each
mouse was transferred to the testing room, placed in the
isopropanol-cleaned chamber for 2 minutes, and then
received a mild foot shock (2 seconds, 0.7 mA) delivered
from the grid floor each time after hearing a 30-second
tone (conditioned stimulus); 2 minutes later, the tone
and the shock would repeat again, and the mouse would
be removed from the chamber and transferred back to
the holding room. 24 hours after the training session,
mice were first tested for freezing behaviors in the same
chamber without the tone stimulus (identical context).
2 hours later, mice were tested for freezing behavior in
an altered environment. Each mouse was transported by
the same experimenter to the same experiment room,
but into the 70% ethanol-cleaned chamber with vanilla
smell (different odor cue), triangle space (different test-
ing space), and smooth white plastic floor (different tact-
ile cue), for a total of 6 minutes. The first 3 minutes
were quiet and the last 3 minutes the tone was played.
Movements of the mouse were recorded by a video cam-
era and analyzed by FreezeFrame software (Version 2;
San Diego Instruments).
Morris water maze assay
Morris water maze tests were performed as previously
published [52-54]. Briefly, mice were trained to locate asquare platform (9 × 9 cm) hidden in quadrant 3 of a
circular water pool within 60 seconds. In the learning
sessions, each mouse was trained in total of 32 trials for
four consecutive days. Each day, each mouse received 2
blocks of training, and in each block, the mouse was
trained for 4 successive trials. At the end of the 32 trials,
the mouse was subjected to a probe test during which
the platform was removed and each mouse would swim
for 60 seconds to search for the platform. APP DSL/PS1
double knock-in mice, together with their wild-type con-
trol group, received a simplified training of 8 trials on
Day 5, in which mice were returned to its holding cage
after each swimming trial. The mice underwent reverse
learning sessions the following week, in which the loca-
tion of the hidden platform was moved from quadrant 3
to quadrant 4. Mice were trained in 4 trials each day for
another four consecutive days. On Day 9, before the re-
verse learning session, mice were exposed to a probe test
of 60 seconds, in which the platform was removed for
the 60-second probing period but placed back at its old
location at the end of the session (to minimize the ex-
tinction effect of probe run). Probe tests on Day 10 ~ 12
were done after the training sessions, and the hidden
platform was put back into the pool at the new location
at the end of each test. For all the swimming sessions,
the training/testing mouse was rested on the platform
for 10 seconds before it was submitted to the next trial
or transferred back to its holding cage. The time for
mice to locate the hidden platform during learning and
reverse learning sessions (escape latency), as well as the
time they spent in each quadrant during the probe tests
(quadrant duration) were recorded by Ethovision track-
ing system (Noldus Information Technologies).
Magnetic Resonance Imaging (MRI)
All mice were initially anesthetized with 5% isoflurane in
oxygen and then transferred to an animal holder within
the magnet where they were maintained on 1.5-2% iso-
flurane in oxygen during imaging. Respiration rate was
monitored using a respiration pad (Small Animal Instru-
ments) and maintained at approximately 30–35 breaths
per minute to minimize motion artifacts during imaging.
Body temperature was monitored with a rectal temperature
probe and was maintained at a constant 37°C using an air
heating system (Small Animal Instruments) throughout the
relative cerebral blood flow (rCBF) measurement. MRI
imaging was carried out utilizing a 9.4 T, Bruker Avance
Biospec Spectrometer with a 21 cm horizontal bore and a
35 mm volume resonator (Bruker BioSpin).
A slice of interest within the brain was selected using
setup scans aligned to where the rostral segment of the
hippocampus first appears. The rCBF was measured
using an arterial spin labeling (ASL) MRI imaging proto-
col. A flow alternating inversion recovery-echo planar
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lized: TR = 7555.38; TE = 16.73; NA = 1; matrix = 64×64;
field of view = 1.5cmx1.5 cm; slice thickness = 1.5 mm.
Both a selective and nonselective ASL image was ac-
quired and the absolute blood flow was then calculated
within two regions of interest within the cortex using
the formula rCBF = λ(1/T1selective – 1/T1global) where
λ is the blood brain partition coefficient which in the
mouse brain is equivalent to 0.9. Five male mice per
genotype of young and old groups, and 8 per genotype
of middle aged group were tested in this experiment.
Transverse Aortic Constriction surgery (TAC)
Transverse aortic constriction and Doppler evaluation of
the blood flow were performed in mice using the
method described in previous publications [55]. In brief,
to produce a transverse aortic constriction, mice were
anesthetized with an initial dose of 5% Isoflurane and
maintained on 2% isoflurane via inhalation, and were
placed on a heating pad at 38.6°C to maintain body
temperature during the surgical procedure. The animal
was placed supine and endotracheal intubation was per-
formed. The endotracheal tube was connected to a
Harvard volume-cycled rodent ventilator cycling at ≈ 150
breaths/minutes and with sufficient volume for adequate
expansion of the lungs, with a tidal volume of approxi-
mately 0.20 -0.25 ml. Oxygen (100%) and maintenance
dose of 1–1.5% isoflurane was supplied to the inflow of
the ventilator during operation. Under a microscope, the
chest cavity was opened and the aortic arch was exposed
after deflection of the thymus. After the transverse aorta
was isolated, a 7–0 nylon suture was placed around the
aorta between the origins of the innominate and left ca-
rotid arteries. A 27-gauge (0.4 mm diameter) needle was
placed against and tied to the aorta with the suture.
Then the needle was removed promptly to yield a constric-
tion with a diameter approximately equal to that of the nee-
dle, and produce a 60-80% constriction. In sham-operated
mice, the suture was placed around the aorta but not tight-
ened. The chest wall was closed and the mice were allowed
to recover from anesthesia under oxygen and a heat lamp
to maintain body temperature. Doppler velocity was mea-
sured in the right and left carotid arteries to confirm that
the blood flow velocity was reduced on the left and in-
creased on the right side and the severity of the constriction
is assessed by the ratio of the left to right peak carotid flow
velocities [55]. Brains from 4 male mice per treatment
group were used for paraffin section/immunohistochemis-
try analysis, and 3 male mice per genotype for 3 month old
group were used in Aβ40 and 42 ELISA analysis.
Statistics analysis
All raw data (from ImageJ, ELISA assay, and behavior tests)
were tabulated in Microsoft Excel. Statistical analyses wereperformed using student t-test in Excel, or two-way
ANOVA in GraphPad Prism4 (GraphPad Software,
www.graphpad.com). Data were presented as average
± SEM (standard error of mean). NS stands for no sig-
nificance; *, p < 0.05; **, p < 0.01; and ***, p < 0.001. For
Morris Water Maze assays, escape latency and distance
traveled data were analyzed using a two-way (geno-
type × trial block) ANOVA with repeated measures.
Search data from the probe trial were analyzed by indi-
vidual one-way ANOVA and Newman-Keuls post com-
parison tests. One-way ANOVA was used to compare
the search time and platform crossing data for the
training quadrant only between wild-type and mutant
mice.
Additional files
Additional file 1: APP DSL mice at old age persist with anxiety
phenotype and deficits in learning and memory.
Additional file 2: APP SL mice over 28 month old have severe
parenchymal plaques and mild CAA.
Additional file 3: MRI scan images of anterior and posterior region
of a brain 1 week post-TAC surgery, showing hypoperfusion on the
left hemisphere only at the anterior region of the brain.
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